Investigator(s): Eric Daar, MD, Loren Miller, MD, MPH, Michael Yeaman, PhD
LOS ANGELES, CA — April 27, 2021 — Investigators at The Lundquist Institute at Harbor-UCLA Medical Center, a leading clinical research center on life-saving vaccines and treatments, have been among the first and foremost to respond against COVID-19. Since March 2020, The Lundquist Institute has led or participated in eight COVID-19 clinical studies and the results of this research have changed the world. This timely and vigorous response was due to the number of early cases and extreme COVID-19 infection surges in south-central Los Angeles.
Investigator(s): Matthew Budoff, MD
LOS ANGELES (April 17, 2021) — Today, The Lundquist Institute announced that Matthew Budoff, MD, Director of Cardiovascular CT at the Institute and Professor of Medicine at the David Geffen School of Medicine at UCLA, will present further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial as Late- Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology.
Investigator(s): Dong Chang, MD
LOS ANGELES (April 13, 2021) — The Lundquist Institute (TLI) Investigator Dong W. Chang, MD, and his colleagues’ study on critically ill patients and ICU treatments was published in JAMA Internal Medicine. The study – “Evaluation of Time-Limited Trials Among Critically Ill Patients with Advanced Medical Illnesses and Reduction of Nonbeneficial ICU Treatments” – found that training physicians to communicate with family members of critically ill patients using a structured approach, which promotes shared decision-making, improved the quality of family meetings.